A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Triple-Negative Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Head and Neck Carcinoma, Squamous Cell|Advanced Solid Tumors
Interventions: DRUG: TAK-659|DRUG: Nivolumab
Sponsor: Calithera Biosciences, Inc